Results 141 to 150 of about 15,170 (273)
Abstract Triple-negative breast cancer (TNBC) is a highly aggressive and heterogeneous disease that often relapses following treatment with standard radiotherapies and cytotoxic chemotherapies. Combination therapies have potential for treating refractory metastatic TNBC.
Zhuoxin “Zora” Zhou +7 more
openaire +2 more sources
A double‐layered shell‐core microneedle patch is developed to co‐deliver FOLFIRINOX, surufatinib, and anti‐PD‐1 for localized chemo‐immunotherapy of PDAC. This strategy achieves sustained tumor suppression, reduces metastasis, and reprograms the TME by enhancing CD8+ T‐cell infiltration and inhibiting Tregs and M2 macrophages infiltration, while ...
Tingting Kong +13 more
wiley +1 more source
Optimized Lipid Nanoparticles with Tail‐Modified Ionizable Lipids for Safer mRNA Delivery
Systematic engineering of hydrophobic tail architecture in vitamin B5‐derived ionizable lipids establishes a comprehensive structure–activity relationship framework for mRNA delivery. Combined lipidtail and formulation optimization identifies TM1‐OPT3‐C, a lipid nanoparticle platform that improves efficacy–safety balance through efficient mRNA delivery,
Seo‐Hyeon Bae +27 more
wiley +1 more source
Engineered exosomal siRNA delivery platform enables systemic, neuron‐targeted RNA transport across the blood–brain barrier. Surface functionalization with rabies virus glycoprotein‐derived peptide facilitates receptor‐mediated transcytosis, achieving efficient cytosolic delivery and robust gene silencing. Targeting RIPK3 suppresses necroptosis, reduces
Chi Zhang +9 more
wiley +1 more source
Cell‐Selective Delivery of RIBOTACs via an Anti‐EGFR Nanobody for Pancreatic Cancer Treatment
This study introduces an innovative strategy for the tumor‐selective catalytic degradation of oncogenic non‐coding RNA by interfacing a ribonuclease‐recruiting small molecule (RIBOTAC) with an EGFR‐targeting nanobody via a CTSB (Cathepsin B)‐responsive linker.
Tianli Luo +15 more
wiley +1 more source
Current landscape of sequencing ADCs in metastatic breast cancer
Antibody-drug conjugates (ADCs) have revolutionized the care of advanced breast cancer. ADCs pair an antibody targeted against a tumor-associated antigen with a cytotoxic payload, aiming to deliver therapy more effectively and with fewer off-target ...
Shannon McLaughlin +9 more
doaj +1 more source
A thermo‐responsive rectal delivery platform integrating probiotic‐derived extracellular vesicles within a hyaluronic acid‐based copolymer enables localized and sustained therapy for ulcerative colitis. The formulation effectively suppresses inflammation, promotes macrophage polarization toward a regenerative phenotype, restores epithelial barrier ...
Ayushi Mairal +5 more
wiley +1 more source
A nanobiohybrid vaccine was designed by constructing a hydrogen‐bonded organic framework coencapsulated with glucose oxidase (GOx) and tumor antigens. This nanobiohybrid vaccine executed a GOx‐catalyzed enzyme reaction that disrupted glucose metabolism and induced redox imbalance in dendritic cells, leading to autophagy‐dependent antigen cross ...
Weidong Wang +5 more
wiley +1 more source
Antibody–Drug Conjugates: Bridging Science and Therapeutics
Antibody–drug conjugates (ADCs) are considered an important advancement in the field of targeted cancer therapy, integrating monoclonal antibodies with cytotoxic payloads to eliminate cancer cells while reducing damage to healthy cells and tissues. These
Kakoli Patnaik +3 more
doaj +1 more source
This study reports D34 as the first PROTAC degrader that targets the 3C protease of picornaviruses. D34 effectively degrades EV71 3C protease via the ubiquitin‐proteasome pathway. More importantly, D34 exhibits a high resistance barrier and shows broad‐spectrum antiviral activity against multiple picornaviruses, highlighting its potential as a novel ...
Weilong Deng +9 more
wiley +1 more source

